The UK boss of one of the biggest pharmaceuticals companies in the world has said he would “not want to be a cancer patient in England” as a 12-week consultation on changing the way patients get access to breakthrough cancer drugs draws to a close.
Erik Nordkamp, managing director of Pfizer UK, said the Government's proposals on reforming the cancer drugs fund would end up failing patients and “set the clock back five years”.
"What is needed is radical reform of the methodology Nice uses for assessing drugs. Other countries are doing this, including Scotland. England is not."
In an interview with The Telegraph, he said England already had one of the worst outcomes for cancer patients among the OECD club of rich nations and was, in his experience, also one of the worst countries in the world, if not the worst, for getting breakthrough drugs to those who need them.
“If the proposals for the cancer drugs fund go through, we will have a repeat of 2011 when treatments weren’t getting through to patients and it will be going back to the status quo,” he continued.